MRI in Clinically Isolated Syndromes and relapsing multiple sclerosis
MRI in Clinically Isolated Syndromes and relapsing multiple sclerosis after single dose (0.1 mmol/kg) and cumulative dose (0.1 + 0.1 mmol/kg) of GADOVIST at 3.0T
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Gadobutrol
Diagnostic agent
What it measured
Main measures
Número de lesiones aumentadas de gadolinium: número total de lesiones aumentadas y no aumentadas detectadas en cada uno de los 4 escaner que se contaran y grabarán.
MRI lesions
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: - Hombres o mujeres, de entre 18 y 50 años Exclusion: - Mujeres embarazadas o en período de lactancia.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Determinar si se detectan mayor número de
Loading reviews and guidelines…
Related trials
- Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Us
Not a drug-phase study · Recruiting
Still running
- Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Mult
Not a drug-phase study · Running, not recruiting
Still running
- Effect of Alemtuzumab on Microglial Activation Positron Emission Tomog
Phase 1 / Phase 2 · Withdrawn
Stopped
- 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Pat
Phase 3 · Completed
Results posted, not judged
- Neuroimaging of the structure and synaptic contacts of the brain of p
Phase 2 · Completed
No results found
- High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multip
Withdrawn
Stopped
History
- Status changed from Ongoing to Status unknown
- Result signal changed from Ongoing to Status unknown
Started
Oct 2009